Xcout IntelOKYO Pharma Limited competitors & alternatives
The 12 closest competitors and alternatives to OKYO Pharma Limited among pharmaceuticals companies — ranked by similarity to what OKYO Pharma Limited actually does, not by market-cap band.
Subscribe to see OKYO Pharma Limited’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About OKYO Pharma Limited
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
OKYO Pharma Limited at a glance
OKYO Pharma Limited is a pharmaceuticals company headquartered in London, United Kingdom, founded in 2018. It is publicly listed (OKYO) with a market capitalisation of $72.4M. Xcout tracks 15 named people at OKYO Pharma Limited, including Robert J. Dempsey (Chief Executive Officer & Executive Director).
OKYO Pharma Limited leadership
- Robert J. DempseyChief Executive Officer & Executive Director
- Robert DempseyChief Executive Officer/Director
- Keeren ShahChief Financial Officer
- Gary S. JacobChief Development Officer & Director
- Flavio MantelliChief Medical Officer
- Gary JacobChief Development Officer/Director
9 more named people on record for OKYO Pharma Limited, with roles, board committees and tenure — see the full roster →
Top 12 OKYO Pharma Limited competitors
Ranked by semantic similarity — how close each company is to OKYO Pharma Limited by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology & Pharmaceuticals
Okogen, Inc. is a biotechnology research company headquartered in Plano, Texas, specializing in innovative eyecare solutions.
Similar pharmaceuticals company
Cloudbreak Pharma is an innovative biotechnology company headquartered in Irvine, California, with operations in Hong Kong. The company focuses on ophthalmic drug development, utilizing a robust research and development engine to create novel therapeutic solutions.
Similar pharmaceuticals company
Laboratoires Théa is a global pharmaceutical company based in France that specializes in ophthalmology and eye care products. Operating through multiple international affiliates and subsidiaries, the company develops and supplies prescription medicines and healthcare solutions to treat various eye diseases.
Similar pharmaceuticals company
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Pharmaceuticals, Biotechnology & Life Sciences
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Similar pharmaceuticals company
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Similar pharmaceuticals company
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Hod Hasharon, Israel. The company focuses on the development and commercialization of treatments for ophthalmic and other serious medical conditions.
Similar pharmaceuticals company
Pharma Two B Ltd. is a late-clinical stage biopharmaceutical company headquartered in Kiryat Ono, Israel. The company focuses on developing pharmaceutical treatments and therapeutic products for neurological and related medical conditions. It has pursued corporate growth initiatives, including planned public market transactions via mergers.
Similar pharmaceuticals company
Santen Pharmaceutical Co., Ltd. is headquartered in Osaka, Japan, and is a global leader in ophthalmological research, development, production, and marketing of related pharmaceuticals and medical devices.
Similar pharmaceuticals company
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Similar pharmaceuticals company
KiOmed Pharma is a Belgian biotechnology company that develops, manufactures, and distributes injectable medical devices based on an exclusive natural chitosan derivative called KiOmedine CM-chitosan. The company serves patients and medical professionals by creating therapeutic solutions and aesthetic products to address osteoarthritis, skin aging, and eye diseases.
Similar pharmaceuticals company
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of OKYO Pharma Limited and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for OKYO Pharma Limitedand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →